MP

Minako Pazdera

General Counsel at Carmot Therapeutics

Minako Pazdera has extensive work experience in the legal and intellectual property field. Minako currently holds the position of Head of Legal and Corporate Secretary at Carmot Therapeutics, Inc., a role they have been in since January 2023. Prior to this, they worked at Lyell Immunopharma as the Vice President Intellectual Property from May 2019 to January 2023. Minako also served as the Vice President of Intellectual Property at Sangamo Therapeutics, Inc. from August 2018 to May 2019.

Minako Pazdera has a strong background in the pharmaceutical industry, having worked at Genentech for several years in various roles. Minako was the Associate General Counsel and Director from June 2015 to July 2018. Before that, they held the position of Assistant General Counsel, Associate Director, and Practice Group Leader from December 2010 to June 2015. Minako also worked as Senior Patent Counsel from April 2010 to November 2010, and as Patent Counsel from April 2007 to March 2010.

Prior to their time at Genentech, Minako Pazdera worked at Ropes & Gray LLP as an Associate/Patent Agent from December 2000 to March 2007. Minako started their career as a Patent Agent/Technical Specialist at Marshall, Gerstein & Borun LLP in 1999.

Overall, Minako Pazdera has a wealth of experience in intellectual property, legal, and corporate roles, particularly in the pharmaceutical industry.

Minako Pazdera's education history begins with a Bachelor of Arts degree in Molecular Cell Biology/Genetics from the University of California, Berkeley, which they obtained from 1989 to 1992. Minako then pursued further education at Carnegie Mellon University, where they earned a Ph.D. in Biological Sciences from 1993 to 1998. Finally, Minako attended Fordham University from 2002 to 2006 and completed their Juris Doctor (J.D.) degree. The field of study for their J.D. degree is not specified.

Links

Previous companies

Genentech logo
Sangamo Therapeutics logo

Timeline

  • General Counsel

    January, 2023 - present

View in org chart